Prevention of exercise-induced bronchoconstriction by inhaled low- molecular-weight heparin

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 2, 1999, Pages 576-581

  Ahmed, Tahir ^a,b   Gonzalez, Brenda J ^a   Danta, Ignacio ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN;

ADOLESCENT; ADULT; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; EXERCISE INDUCED ASTHMA; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 0032799285     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.2.9812076     Document Type: Article

References (42)

1. 1. Jacques, L. B. 1979. Heparins - anionic polyelectrolyte drugs. Pharmacol. Rev. 31:99-166.
2. 2. Lindahl, U. 1989. Biosynthesis of heparin and related polysaccharides. In D. A. Lane and U. Lindahl, editors. Heparin, Chemical and Biological Properties, Clinical Applications. CRC Press, Boca Raton, FL. 159-189.
3. 3. Linhardt, R. J., and D. Loganathan. 1990. Heparin, heparinoids and heparin oligosaccharides: structure and biological activities. In C. G. Gebelein, editor. Biomimetic Polymers. Plenum Press, New York. 135-173.
4. 4. Burgess, W. H., and T. Maciag. 1989. The heparin-binding (fibroblast) growth factor family of proteins. Ann. Rev. Biochem. 58:575-606.
5. 1. J. Cell. Physiol. 152:430-440.
6. 6. Wright, T. C., Jr., J. J. Castellot, Jr., M. Petitou, J. Lormeau, J. Choay, and M. J. Karnovsky. 1989. Structural determinants of heparin's growth inhibitory activity: interdependence of oligosaccharide size and charge. J. Biol. Chem. 264:1534-1542.
7. 7. Folkman, J., and D. E. Ingber. 1989. Angiogenesis: regulatory role of heparin and related molecules. In D. A. Lane and U. Lindahl, editors. Heparin. Edward Arnold, London. 317-333.
8. 8. Schwartz, L. B., and T. R. Bradford. 1986. Regulation of tryptase from human lung mast cells by heparin: stabilization of the active tetramer. J. Biol. Chem. 261:7372-7379.
9. 1 antitrypsin: evidence for a heparin-induced cleaved form of the inhibitor. Arch. Biochem. Biophys. 347:19-29.
10. 10. Dolowitz, D. A., and T. F. Dougherty. 1960. The use of heparin as an anti-inflammatory agent. Laryngoscope 70:873-884.
11. 11. Seeds, E. A. M., J. Hanss, and C. P. Page. 1993. The effect of heparin and related proteoglycans on allergen and PAF-induced cosinophil infiltration. J. Lipid. Mediat. 7:269-278.
12. 12. Matzner, Y., G. Marx, R. Drexler, and A. Eldor. 1984. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb. Haemost. 52:134-137.
13. 13. Ahmed, T., W. M. Abraham, and J. D'Brot. 1992. Effects of inhaled heparin on immunologic and non-immunologic bronchoconstrictor responses in sheep. Am. Rev. Respir. Dis. 145:566-570.
14. 14. Ahmed, T., J. Garrigo, and I. Danta. 1993. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N. Engl. J. Med. 329:90-95.
15. 15. Garrigo, J., I. Danta, and T. Ahmed. 1996. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am. J. Respir. Crit. Care Med. 153:1702-1707.
16. 16. Bowler, S. D., S. M. Smith, and P. S. Lavercombe. 1993. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am. Rev. Respir. Dis. 147:160-163.
17. 17. Diamant, Z., M. C. Timmers, H. van der Veen, C. P. Page, F. J. van der Meer, and P. J. Sterk. 1996. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am. J. Respir. Crit. Care Med. 153:1790-1795.
18. 18. Cifonelli, J. A. 1974. The relationship of molecular weight, sulfate content and distribution to anticoagulant activity of heparin preparations. Carbohydrate Res. 37:145-154.
19. 19. Laurent, T. C., A. Tengblad, L. Thunberg, M. Höök, and U. Lindahl. 1978. The molecular-weight-dependence of the anticoagulant activity of heparin. Biochem. J. 175:691-701.
20. 20. Martinez-Salas, J., R. Mendelssohn, W. M. Abraham, B. Hsiao, and T. Ahmed. 1998. Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence. J. Appl. Physiol. 84:222-228.
21. 21. Ahmed, T., C. S. Kim, and I. Danta. 1988. Inhibition of antigen-induced bronchoconstriction by a new calcium antagonist, gallopamil: comparison with cromolyn sodium. J. Allergy Clin. Immunol. 81:852-858.
22. 22. Redini, F., J. Tixier, M. Petitou, J. Choay, L. Robert, and W. Hornebeck. 1988. Inhibition of leukocyte elastase by heparin and its derivatives. Biochem. J. 252:515-519.
23. 23. Latimer, K. M., P. M. O'Byrne, M. M. Morris, R. Roberts, and F. E. Hargreave. 1983. Bronchoconstriction stimulated by airway cooling: better protection with combined inhalation of terbutaline sulphate and cromolyn sodium than with either alone. Am. Rev. Respir. Dis. 128: 440-443.
24. 24. O'Byrne, P. M., N. C. Thomson, M. Morris, R. S. Roberts, E. E. Daniel, and F. E. Hargreave. 1983. The protective effect of inhaled chlorpheniramine and atropine on the bronchoconstriction stimulated by airway cooling. Am. Rev. Respir. Dis. 128:611-617.
25. 25. Patel, K. R. 1981. Calcium antagonists in exercise-induced asthma. B.M.J. 282:932-933.
26. 26. Bianco, S., A. Vaghi, M. Robuschi, and M. Pasargiklian. 1988. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet 2:252-255.
27. 4-receptor antagonist. N. Engl. J. Med. 323:1736-1739.
28. 28. Israel, E., R. Dermarkarian, M. Rosenberg, R. Sperling, G. Taylor, P. Rubin, and J. M. Drazen. 1990. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N. Engl. J. Med. 323:1740-1744.
29. 29. Harenberg, J., R. Malsch, M. Angelescu, C. Lang, H. C. Michaelis, H. Wolf, and D. L. Heene. 1996. Anticoagulant effects of tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin. Blood Coag. Fibrinol. 7:477-483.
30. 30. Leff, J. A., W. W. Busse, D. Pearlman, E. A. Bronsky, J. Kemp, L. Hendeles, R. Dockhorn, S. Kundu, J. Zhang, B. C. Seidenberg, and T. F. Reiss. 1998. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. 339:147-152.
31. 31. O'Byrne, P. M., E. Israeli, and J. M. Drazen. 1997. Anti-leukotrienes in the treatment of asthma. Ann. Intern. Med. 127:472-480.
32. 32. Robuschi, M., E. Riva, L. M. Fuccella, E. Vida, R. Barnabe, M. Rossi, G. Gambaro, S. Spagnotto, and S. Bianco. 1992. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am. Rev. Respir. Dis. 145:1285-1288.
33. 33. Ahmed, T., J. D'Brot, W. M. Abraham, J. Lucio, R. Mendelssohn, M. J. Robinson, S. Shakir, and B. SanPedro. 1996. Heterogeneity of allergic airway responses in sheep: differences in signal transduction? Am. J. Respir. Crit. Care Med. 154:843-849.
34. 34. Boneu, B., M. R. Buchanan, C. Caranobe, A. M. Gabaig, D. Dupouy, P. Sie, and J. Hirsch. 1987. The disappearance of a low molecular weight heparin fraction (Cy216) differs from standard heparin in rabbits. Thromb. Res. 46:845-853.
35. 35. Ahmed, T., T. Syriste, J. Lucio, W. M. Abraham, M. Robinson, and J. D'Brot. 1993. Inhibition of antigen-induced airway and cutaneous responses by heparin: a pharmacodynamic study. J. Appl. Physiol. 74: 1492-1498.
36. 36. Ahmed, T., C. Campo, M. K. Abraham, J. F. Molinari, W. M. Abraham, D. Ashkin, T. Syriste, L. O. Andersson, and C. M. Svahn. 1997. Inhibition of antigen-induced bronchoconstriction, airway hyperresponsiveness and mast cell degranulation by a non-anticoagulant heparin: comparison with a low molecular weight heparin. Am. J. Respir. Crit. Care Med. 155:1848-1855.
37. 37. Campo, C., J. F. Molinari, J. Ungo, and T. Ahmed. 1999. Molecular weight-dependent effects of non-anticoagulant heparins on allergic airway responses. J. Appl. Physiol. 86:549-557.
38. 38. Lucio, J., J. D'Brot, C. B. Guo, W. M. Abraham, L. M. Lichtenstein, A. Kagey-Sobotka, and T. Ahmed. 1992. Immunologic mast cell-mediated responses and histamine release are attenuated by heparin. J. Appl. Physiol. 73:1093-1101.
39. 3-mediated mast cell degranulation? J. Appl. Physiol. 76:893-901.
40. 40. Abraham, W. M., M. K. Abraham, and T. Ahmed. 1996. Protective effect of heparin on immunologically induced tracheal smooth muscle contraction in vivo. Int. Arch. Allergy Immunol. 110:79-84.
41. 41. Molinari, J. F., C. Campo, W. M. Abraham, J. Martinez-Salas, and T. Ahmed. 1998. Inhibition of antigen-induced airway hyperresponsiveness by ultralow molecular-weight heparin. Am. J. Respir. Crit. Care Med. 157:887-893.
42. 42. Tones, M. A., M. D. Bootman, B. F. Higgins, D. A. Lane, G. F. Pay, and U. Lindahl. 1989. The effect of heparin on the inositol 1,4,5-trisphosphate receptor in rat liver microsomes: dependence on sulphate content and chain length. FEBS Lett. 252:105-108.